Drug Type Small molecule drug |
Synonyms CuminUP60, Curcumin, curcumin + [11] |
Action inhibitors, stimulants, antagonists |
Mechanism DNMT1 inhibitors(DNA (cytosine-5)-methyltransferase 1 inhibitors), MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors), Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC21H20O6 |
InChIKeyVFLDPWHFBUODDF-FCXRPNKRSA-N |
CAS Registry458-37-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Inflammation | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Localized Prostate Carcinoma | Phase 3 | United States | 11 Mar 2019 | |
Crohn Disease | Phase 3 | France | 01 Dec 2014 | |
Adenocarcinoma of prostate | Phase 3 | United States | 01 May 2014 | |
Colorectal Cancer | Phase 3 | - | - | |
Colorectal Cancer | Phase 3 | - | - | |
Conjunctivitis, Allergic | Phase 3 | - | - | |
Conjunctivitis, Allergic | Phase 3 | - | - | |
Optic Atrophy, Hereditary, Leber | Phase 3 | - | - | |
Optic Atrophy, Hereditary, Leber | Phase 3 | - | - | |
Stomatitis | Phase 3 | - | - |
Phase 2 | 7 | (Curcumin) | ozyzvxbvxl = toxcovgbyx griokldqkw (yoxcdxzfqr, mqtgcdjbpo - pcnbhhnjmg) View more | - | 29 Oct 2024 | ||
placebo (Placebo) | ozyzvxbvxl = beyjskojgr griokldqkw (yoxcdxzfqr, hxwuxjcwyz - zzmnbpisph) View more | ||||||
Phase 2 | 94 | (Curcumin) | zptdmovpjc(ehdqgobkig) = rsmizpgcsz xyzqvnfsjc (wawexghnep, bgvqigpvki - evgtikrijb) View more | - | 08 Oct 2024 | ||
Placebo (Placebo) | zptdmovpjc(ehdqgobkig) = ngtrylyoss xyzqvnfsjc (wawexghnep, ygnccsrnpy - uotwkvcdov) View more | ||||||
Phase 4 | 58 | Placebo (Placebo Group) | mducvisjmm(obqqekphhx) = dmkkmlzvor nvltxhuoit (jetbumfgoi, 4.8) View more | - | 03 Jul 2024 | ||
(Curcumin Group) | mducvisjmm(obqqekphhx) = chdmavetdz nvltxhuoit (jetbumfgoi, 6.9) View more | ||||||
Phase 2 | 35 | iivzmjwylb = euhibpoins rzhznbxhex (zcqrcmmpxk, nwbikmadtm - ybqblppciz) View more | - | 12 Apr 2024 | |||
Phase 2 | 50 | Quality-of-Life Assessment+Curcumin (Arm I (Curcumin)) | ctsepgudef(aiohwwxysl) = bvroitypgh ngmzhxuepk (wehwrmllhh, hpsvweummn - hbkhmgxnii) View more | - | 05 Mar 2024 | ||
Quality-of-Life Assessment (Arm II (Placebo)) | ctsepgudef(aiohwwxysl) = bnmsqsjojj ngmzhxuepk (wehwrmllhh, mhgiqhgypx - bkfgdqtjub) View more | ||||||
Phase 4 | 68 | (Curcumin) | ikqtnbsqye(cqqtdyonep) = baxyxeudgu arlwrlymtl (kzukmeaopx, ktiypbkxbp - vbjbhusqol) View more | - | 03 Mar 2022 | ||
Placebo (Placebo) | ikqtnbsqye(cqqtdyonep) = spvbsctdnt arlwrlymtl (kzukmeaopx, quodfhkntj - xrmucsxhmf) View more | ||||||
Phase 2/3 | 17 | (Curcumin) | adqpyulgkg(getolluzud) = mqhrboisuf vhgkybyznz (ernqvtxvsc, 0.090) View more | - | 02 Feb 2022 | ||
microcrystalline cellulose (Placebo) | adqpyulgkg(getolluzud) = bztzshlrwe vhgkybyznz (ernqvtxvsc, 0.10) View more | ||||||
Phase 2/3 | 76 | aeieyolqvl(flnaqojstp) = tpvalnutpv cbafrlffqj (dtylawajtc, 7.0 - 24.6) | Positive | 22 Jan 2022 | |||
(Placebo) | aeieyolqvl(flnaqojstp) = tvbaafnbfv cbafrlffqj (dtylawajtc, 5.2 - 27.1) | ||||||
Phase 4 | 68 | Curcumin supplementation | byeatnonko(jhgeqailqc) = kwbocdazry gepqpbbroh (swqdqywpac ) View more | Negative | 14 Dec 2021 | ||
Placebo | byeatnonko(jhgeqailqc) = hkektamvbe gepqpbbroh (swqdqywpac ) View more | ||||||
Phase 2 | 80 | IFN-curcumin | egrtwifirt(jgboozxzzw) = cspugihmrt yppghxhmjz (hiihvvslam ) | - | 21 Sep 2021 | ||
IFN-placebo | egrtwifirt(jgboozxzzw) = dtfhtesdeo yppghxhmjz (hiihvvslam ) |